05th July 2021
Consilium Strategic Communications Advises Biotalys on its Successful €54.6 Million Initial Public Offering
London, 5 July 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised Biotalys on its successful Initial Public Offering (IPO) on Euronext Brussels.
Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for more sustainable and safer food. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective products with a favourable safety profile that aim to address key crop pests and diseases across the whole value chain, from farm to fork.
Biotalys raised approximately €47.5 million, or approximately €54.6 million, assuming the exercise in full of the over-allotment option, to fund the development of its existing pipeline, the continued improvement and optimisation of its AGROBODY Foundry™ platform, and its go-to-market strategy and for general corporate purposes. On listing, Biotalys had a market capitalisation of approximately €225.2 million.
The Consilium team was led by Amber Fennell and supported by Chris Gardner, Chris Welsh, Kris Lam, Alex Gunter and Aaron Kelly. Consilium continues to advise the company on its financial communications and investor relations as a publicly listed company. Berenberg and KBC Securities acted as Joint Global Coordinators and Joint Bookrunners, Belfius Bank as Joint Bookrunner and Oppenheimer Europe Ltd. through Oppenheimer & Co. Inc. as Lead U.S. Bookrunner.
“We are proud to have supported such a transformational company as Biotalys to make its public debut on Euronext Brussels. Feeding the world safely and sustainably is one of mankind’s biggest challenges and Biotalys’ unique approach can help support that. We very much look forward to continuing to work with Biotalys to communicate its compelling story as a public company.”
Amber FennellPartner and Co-Founder of Consilium Strategic Communications
“Consilium’s support has been instrumental as we transitioned from a private to a public company. Their team helped us in shaping and communicating the differentiated elements of our story and bring out the potential of our AGROBODY Foundry™ platform to investors. We look forward to continuing our great relationship as a listed company.”
Patrice SellèsChief Executive Officer of Biotalys
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for more sustainable and safer food. Based on its novel AGROBODY™ technology platform, Biotalys aims to develop a strong and diverse pipeline of effective products with a favorablefavourable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has raised €62.8 million (US$74.9 million) to date from Belgian and international investors. The Company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.